Favipiravir (T-705)
中文名称：法匹拉韦
Favipiravir (T-705)是一种有效的选择性RNA-dependent RNA polymerase抑制剂，用于治疗流感病毒感染。
Favipiravir (T-705) Chemical Structure
CAS: 259793-96-9
客户使用Selleck的Favipiravir (T-705)发表文献20篇
客户使用该产品的2个实验数据
产品质控
批次：
纯度：
99.97%
99.97
Favipiravir (T-705)相关产品
| 相关靶点 | tRNA synthetase RdRp DNA synthesis helicase ribonucleotide reductase | 点击展开 |
|---|---|---|
| 相关化合物库 | FDA药物库 天然产物库 凋亡分子化合物库 DNA损伤/ DNA修复化合物库 细胞周期化合物库 | 点击展开 |
相关信号通路图
DNA/RNA Synthesis抑制剂选择性比较
细胞实验数据示例
| 细胞系 | 实验类型 | 给药浓度 | 孵育时间 | 活性描述 | 文献信息 |
|---|---|---|---|---|---|
| MDCK | Antiviral assay | 1 hr | 3 days | Antiviral activity against Influenza A virus (A/Taiwan/1/1986(H1N1)) infected in MDCK cells assessed as inhibition of virus-induced cytopathogenicity at 1 hr post-infection measured after 3 days by fluorescein-diacetate based fluorimetric analysis, EC50 = 6.95 μM. | 23419738 |
| Vero | Antiviral assay | 6400 uM | up to 12 hrs | Antiviral activity against Yellow fever virus 17D infected in African green monkey Vero cells assessed as time required for inhibition of viral replication at 6400 uM up to 12 hrs post-viral infection, NULL = NULL μM. | 18955536 |
| MDCK | Antiviral assay | 10 uM | up to 8 hrs | Antiviral activity against Influenza A virus (A/chicken/Hubei/327/2004(H5N1)) infected in MDCK cells assessed as inhibition of early stages of viral replication at 10 uM up to 8 hrs by crystal violet staining based plaque reduction assay dependent time-of, NULL = NULL μM. | 30292897 |
| MDCK | Antiviral assay | 100 uM | 12 hrs | Antiviral activity against Influenza virus A/X-31 infected in MDCK cells assessed as inhibition of one cycle viral RNA synthesis at 100 uM preincubated with cells for 12 hrs followed by viral infection measured after 10 hrs post infection by RT-qPCR metho, NULL = NULL μM. | 29906392 |
| MDCK | Antiviral assay | 250 uM | 10 hrs | Antiviral activity against Influenza virus A/X-31 infected in MDCK cells assessed as inhibition of one cycle viral RNA sytheis at 250 uM added together with virus and measured at 10 hrs post infection by RT-qPCR method, NULL = NULL μM. | 29906392 |
| MDCK | Antiviral assay | 128 uM | Antiviral activity against adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza A virus (A/pdm/Mexico/4604/2009(H1N1)) harboring M2 V28I, S31N mutant infected in MDCK cells assessed as determination of viral titer in cell culture at 128 uM af, NULL = NULL μM. | 20350949 | |
| MDCK | Antiviral assay | 128 uM | Antiviral activity against adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza A virus (A/pdm/California/04/2009(H1N1)) harboring M2 V28I, S31N mutant infected in MDCK cells assessed as determination of viral titer in cell culture at 128 uM , NULL = NULL μM. | 20350949 | |
| MDCK | Antiviral assay | 3 days | Antiviral activity against adamantane-, oseltamivir-, zanamivir-susceptible Influenza A virus (A/Ann Arbor/6/1960(H2N2)) infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain, EC50 = 0.38 μM. | 20350949 | |
| MDCK | Antiviral assay | 3 days | Antiviral activity against adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza A virus (A/New York/34/2008(H1N1)) harboring M2 L26I mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysi, EC50 = 0.19 μM. | 20350949 | |
| MDCK | Antiviral assay | 3 days | Antiviral activity against adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza A virus (A/Florida/01/2009(H3N2)) harboring M2 S31N mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis, EC50 = 0.45 μM. | 20350949 | |
| MDCK | Antiviral assay | 3 days | Antiviral activity against oseltamivir-susceptible zanamivir-, adamantane-resistant Influenza B virus B/Memphis/20/1996 harboring neuraminidase R152K mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic ana, EC50 = 0.57 μM. | 20350949 | |
| MDCK | Antiviral assay | 3 days | Antiviral activity against adamantane-, oseltamivir-, zanamivir-susceptible Influenza A virus (A/Swine/South Dakota/03/2008(H1N1)) infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet, EC50 = 0.83 μM. | 20350949 | |
| MDCK | Antiviral assay | 3 days | Antiviral activity against adamantane-susceptible zanamivir-, oseltamivir-resistant Influenza A virus (A/Brazil/1633/2008(H1N1)) harboring neuraminidase Q136K mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by micros, EC50 = 0.83 μM. | 20350949 | |
| MDCK | Antiviral assay | 3 days | Antiviral activity against adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza A virus (A/pdm/California/05/2009 (H1N1)) harboring M2 V28I, S31N mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by micros, EC50 = 0.83 μM. | 20350949 | |
| MDCK | Antiviral assay | 3 days | Antiviral activity against adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza A virus (A/pdm/New York/18/2009 (H1N1)) harboring M2 V28I, S31N mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microsco, EC50 = 0.89 μM. | 20350949 | |
| MDCK | Antiviral assay | 3 days | Antiviral activity against adamantane-, zanamivir-susceptible oseltamivir-resistant Influenza A virus (A/turkey/Minnesota/833/1980(H4N2)) harboring neuraminidase E119G mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days , EC50 = 0.89 μM. | 20350949 | |
| MDCK | Antiviral assay | 3 days | Antiviral activity against adamantane-, oseltamivir-, zanamivir-susceptible Influenza A virus (A/turkey/Minnesota/833/1980(H4N2)) infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet , EC50 = 0.96 μM. | 20350949 | |
| MDCK | Antiviral assay | 3 days | Antiviral activity against adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza A virus (A/pdm/Mexico/4604/2009 (H1N1)) harboring M2 V28I, S31N mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microsco, EC50 = 1.21 μM. | 20350949 | |
| MDCK | Antiviral assay | 3 days | Antiviral activity against adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza B virus B/Memphis/20/1996 infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain, EC50 = 1.21 μM. | 20350949 | |
| MDCK | Antiviral assay | 1 hr | Antiviral activity against Influenza B virus (B/Brisbane/60/2008) infected in MDCK cells assessed as inhibition of virus-induced cytopathogenicity at 1 hr post-infection measured after 3 days by fluorescein-diacetate based fluorimetric analysis, EC50 = 1.32 μM. | 23419738 | |
| MDCK | Antiviral assay | 3 days | Antiviral activity against adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza A virus (A/pdm/California/07/2009 (H1N1)) harboring M2 V28I, S31N mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by micros, EC50 = 1.4 μM. | 20350949 | |
| MDCK | Antiviral assay | 3 days | Antiviral activity against adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza B virus (B/Rochester/01/2001) infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain, EC50 = 1.4 μM. | 20350949 | |
| MDCK | Antiviral assay | 3 days | Antiviral activity against adamantane-, oseltamivir-, zanamivir-susceptible Influenza A virus (A/Georgia/17/2006(H1N1)) infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain, EC50 = 1.46 μM. | 20350949 | |
| MDCK | Antiviral assay | 3 days | Antiviral activity against adamantane-, oseltamivir-, zanamivir-susceptible Influenza A virus (A/turkey/VA/4529/2002 (H7N2)) infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain, EC50 = 1.53 μM. | 20350949 | |
| MDCK | Antiviral assay | 3 days | Antiviral activity against adamantane-, zanamivir-susceptible oseltamivir-resistant Influenza A virus (A/Florida/21/2008(H1N1)) harboring neuraminidase H274Y mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microsc, EC50 = 1.59 μM. | 20350949 | |
| MDCK | Antiviral assay | 3 days | Antiviral activity against adamantane-, oseltamivir-, zanamivir-susceptible Influenza A virus (A/duck/Vietnam/NCVD93/2007 clade 2.3.4 (H5N1)) infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using cry, EC50 = 1.59 μM. | 20350949 | |
| MDCK | Antiviral assay | 3 days | Antiviral activity against oseltamivir-susceptible zanamivir-, adamantane-resistant Influenza B virus (B/Rochester/01/2001) harboring neuraminidase D198N mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic, EC50 = 1.72 μM. | 20350949 | |
| MDCK | Antiviral assay | 3 days | Antiviral activity against adamantane-, oseltamivir-, zanamivir-susceptible Influenza A virus (A/Brazil/1067/2008(H1N1)) infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain, EC50 = 1.85 μM. | 20350949 | |
| MDCK | Antiviral assay | 1 hr | Antiviral activity against Influenza B virus (B/Lee/40) infected in MDCK cells assessed as inhibition of virus-induced cytopathogenicity at 1 hr post-infection measured after 3 days by fluorescein-diacetate based fluorimetric analysis, EC50 = 1.93 μM. | 23419738 | |
| MDCK | Antiviral assay | 1 hr | Antiviral activity against Influenza B virus (B/Panama/45/1990) infected in MDCK cells assessed as inhibition of virus-induced cytopathogenicity at 1 hr post-infection measured after 3 days by fluorescein-diacetate based fluorimetric analysis, EC50 = 1.94 μM. | 23419738 | |
| MDCK | Antiviral assay | 3 days | Antiviral activity against adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza A virus (A/pdm/California/04/2009 (H1N1)) harboring M2 V28I, S31N mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by micros, EC50 = 1.97 μM. | 20350949 | |
| MDCK | Antiviral assay | 3 days | Antiviral activity against adamantane-, oseltamivir-, zanamivir-susceptible Influenza A virus (A/swine/Michigan/09/2007 (H1N2)) harboring M2 V27I, V28D mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic a, EC50 = 2.23 μM. | 20350949 | |
| MDCK | Antiviral assay | 3 days | Antiviral activity against adamantane-, oseltamivir-, zanamivir-susceptible Influenza A virus (A/Ecuador/5179/2008(H1N1)) infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain, EC50 = 2.48 μM. | 20350949 | |
| MDCK | Antiviral assay | 3 days | Antiviral activity against adamantane-, zanamivir-susceptible oseltamivir-resistant Influenza A virus (A/Georgia/20/2006(H1N1)) harboring neuraminidase H274Y mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microsc, EC50 = 2.55 μM. | 20350949 | |
| MDCK | Antiviral assay | 24 hrs | Antiviral activity against Influenza A virus A/WSN/33(H1N1) infected in MDCK cells assessed as inhibition of neuraminidase activity using 2'-(4-methylumbelliferyl)-alpha-D-N-acetylneuraminic acid substrate pretreated with cells for 24 hrs followed by vira, EC50 = 2.7 μM. | 27120583 | |
| MDCK | Antiviral assay | 1 hr | Antiviral activity against Influenza B virus (B/Taiwan/2/62) infected in MDCK cells assessed as inhibition of virus-induced cytopathogenicity at 1 hr post-infection measured after 3 days by fluorescein-diacetate based fluorimetric analysis, EC50 = 2.84 μM. | 23419738 | |
| MDCK | Antiviral assay | 3 days | Antiviral activity against adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza A virus (A/Wisconsin/16/2008(H1N1)) harboring neuraminidase H274Y mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by micros, EC50 = 2.87 μM. | 20350949 | |
| MDCK | Antiviral assay | 3 days | Antiviral activity against adamantane-, oseltamivir-, zanamivir-resistant Influenza A virus (A/Idaho/01/2009(H1N1)) harboring neuraminidase H274Y mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysi, EC50 = 2.93 μM. | 20350949 | |
| MDCK | Antiviral assay | 3 days | Antiviral activity against adamantane-, oseltamivir-, zanamivir-resistant Influenza B virus (B/Illinois/03/2008) harboring neuraminidase E119A mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis u, EC50 = 3 μM. | 20350949 | |
| MDCK | Antiviral assay | 3 days | Antiviral activity against adamantane-, zanamivir-susceptible oseltamivir-resistant Influenza A virus (A/Washington/10/2008(H1N1)) harboring M2 S31N mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic anal, EC50 = 3.25 μM. | 20350949 | |
| MDCK | Antiviral assay | 3 days | Antiviral activity against adamantane-, oseltamivir-, zanamivir-susceptible Influenza A virus (A/California/27/2007(H1N1)) infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain, EC50 = 3.63 μM. | 20350949 | |
| MDCK | Antiviral assay | 3 days | Antiviral activity against adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza B virus (B/Illinois/47/2005) infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain, EC50 = 4.01 μM. | 20350949 | |
| MDCK | Antiviral assay | 3 days | Antiviral activity against adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza A virus (A/New Hampshire/01/2009(H3N2)) harboring M2 S31N mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic an, EC50 = 4.08 μM. | 20350949 | |
| MDCK | Antiviral assay | 3 days | Antiviral activity against adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza A virus (A/Massachusetts/03/2009(H3N2)) harboring M2 S31N mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic an, EC50 = 4.2 μM. | 20350949 | |
| MDCK | Antiviral assay | 3 days | Antiviral activity against adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza A virus (A/Washington/01/2007(H3N2)) harboring M2 S31N mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analy, EC50 = 4.46 μM. | 20350949 | |
| MDCK | Antiviral assay | 3 days | Antiviral activity against adamantane-, oseltamivir-, zanamivir-susceptible Influenza A virus (A/Swine/Texas/14/2008 (H1N1)) harboring M2 V27T, V28D mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic anal, EC50 = 4.52 μM. | 20350949 | |
| MDCK | Antiviral assay | 3 days | Antiviral activity against adamantane-susceptible zanamivir-, oseltamivir-resistant Influenza A virus (A/Santiago/5248/2008(H1N1)) harboring neuraminidase D198E mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by micr, EC50 = 4.7 μM. | 20350949 | |
| MDCK | Antiviral assay | 1 hr | Antiviral activity against Influenza A virus (A/Hong kong/8/1968(H2N3)) infected in MDCK cells assessed as inhibition of virus-induced cytopathogenicity at 1 hr post-infection measured after 3 days by fluorescein-diacetate based fluorimetric analysis, EC50 = 4.71 μM. | 23419738 | |
| MDCK | Antiviral assay | 3 days | Antiviral activity against adamantane-, zanamivir-susceptible oseltamivir-resistant Influenza A virus (A/New Jersey/15/2007(H1N1)) harboring neuraminidase H274Y mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by micr, EC50 = 4.9 μM. | 20350949 | |
| Vero | Antiviral assay | 7 to 8 days | Antiviral activity against Junin virus Candid-1 in Vero cells assessed as inhibition of virus-induced visual cytopathic effect after 7 to 8 days, EC50 = 5 μM. | 17606691 | |
| MDCK | Antiviral assay | 3 days | Antiviral activity against adamantane-, zanamivir-susceptible oseltamivir-resistant Influenza A virus (A/North Carolina/02/ 2009(H1N1)) harboring M2 S31N mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic, EC50 = 5.03 μM. | 20350949 | |
| MDCK | Antiviral assay | 3 days | Antiviral activity against oseltamivir-susceptible zanamivir-, adamantane-resistant Influenza B virus (B/Michigan/20/2005) harboring neuraminidase H274Y mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic , EC50 = 5.03 μM. | 20350949 | |
| MDCK | Antiviral assay | 3 days | Antiviral activity against adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza A virus (A/Vietnam/1203/2004 clade 1 (H5N1)) harboring M2 L26I, S31N mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by mic, EC50 = 5.22 μM. | 20350949 | |
| MDCK | Antiviral assay | 3 days | Antiviral activity against adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza B virus (B/New York/22/2008) infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain, EC50 = 5.3 μM. | 20350949 | |
| MDCK | Antiviral assay | 3 days | Antiviral activity against oseltamivir-susceptible zanamivir-, adamantane-resistant Influenza A virus (A/Wuhan/395/1995-like (H3N2)) harboring neuraminidase E119V mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by mi, EC50 = 5.41 μM. | 20350949 | |
| MDCK | Antiviral assay | 3 days | Antiviral activity against adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza A virus (A/Wuhan/395/1995-like (H3N2)) infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal viole, EC50 = 5.99 μM. | 20350949 | |
| Vero | Antiviral assay | 7 to 8 days | Antiviral activity against Pichinde virus An 4763 in Vero cells assessed as inhibition of virus-induced visual cytopathic effect after 7 to 8 days, EC50 = 6 μM. | 17606691 | |
| Vero | Antiviral assay | 7 to 8 days | Antiviral activity against Tacaribe virus TRVL11573 in Vero cells assessed as inhibition of virus-induced visual cytopathic effect after 7 to 8 days, EC50 = 6 μM. | 17606691 | |
| MDCK | Antiviral assay | 3 days | Antiviral activity against Influenza virus B/Ned/537/05 infected in MDCK cells assessed as reduction in viral replication at 3 days post infection by formazan-based MTS assay, EC50 = 8.3 μM. | 29906392 | |
| MDCK | Antiviral assay | 3 days | Antiviral activity against Influenza virus B/Ned/537/05 infected in MDCK cells assessed as reduction in viral replication at 3 days post infection by microscopic analysis, EC50 = 9 μM. | 29906392 | |
| MDCK | Antiviral assay | 3 days | Antiviral activity against adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza A virus (A/New York/107/2003(H7N2)) harboring M2 V28A, S31N mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic , EC50 = 10.2 μM. | 20350949 | |
| MDCK | Antiviral assay | 3 days | Antiviral activity against Influenza virus A/X-31 infected in MDCK cells assessed as reduction in viral replication at 3 days post infection by microscopic analysis, EC50 = 24 μM. | 29906392 | |
| MDCK | Antiviral assay | 3 days | Antiviral activity against Influenza virus A/X-31 infected in MDCK cells assessed as reduction in viral replication at 3 days post infection by formazan-based MTS assay, EC50 = 26 μM. | 29906392 | |
| MDCK | Antiviral assay | 0 to 2 hrs | Inhibition of influenza A virus infected in MDCK cells assessed as inhibition of viral load treated with compound at 0 to 2 hrs post-infection by RT-qPCR method based time of addition assay, NULL = NULL μM. | 30192544 | |
| MDCK | Antiviral assay | 5 to 8 hrs | Inhibition of influenza A virus infected in MDCK cells assessed as inhibition of viral load treated with compound at 5 to 8 hrs post-infection by RT-qPCR method based time of addition assay, NULL = NULL μM. | 30192544 | |
| MDCK | Antiviral assay | 0 to 10 hrs | Inhibition of influenza A virus infected in MDCK cells assessed as inhibition of viral load treated with compound at 0 to 10 hrs post-infection by RT-qPCR method based time of addition assay, NULL = NULL μM. | 30192544 | |
| MDCK | Antiviral assay | 2 to 5 hrs | Inhibition of influenza A virus infected in MDCK cells assessed as inhibition of viral load treated with compound at 2 to 5 hrs post-infection by RT-qPCR method based time of addition assay, NULL = NULL μM. | 30192544 | |
| MDCK | Antiviral assay | Antiviral activity against oseltamivir-susceptible zanamivir-, adamantane-resistant Influenza A virus (A/Bethesda/956/2006(H3N2)) harboring neuraminidase R292K mutant and M2 S31N mutant infected in MDCK cells assessed as inhibition of viral replication af, EC50 = 1.21 μM. | 20350949 | ||
| MDCK | Antiviral assay | Antiviral activity against adamantane-, oseltamivir-, zanamivir-susceptible Influenza A virus (A/chicken/Vietnam/NCVD103/2007 clade 2.3.4 (H5N1)) harboring neuraminidase I222T mutant infected in MDCK cells assessed as inhibition of viral replication after, EC50 = 1.27 μM. | 20350949 | ||
| MDCK | Antiviral assay | Inhibition of viral replication of influenza A virus (A/Hong Kong/213/03(H5N1)) and influenza A virus (A/Ann Arbor/6/60(H2N2)) hybrid virus in MDCK cells by virus yield reduction assay, EC90 = 1.3 μM. | 17194832 | ||
| MDCK | Antiviral assay | Antiviral activity against adamantane-, oseltamivir-, zanamivir-resistant Influenza A virus (A/Vietnam/HN30408/2005 N294S clade 1 (H5N1)) harboring M2 L26I, S31N mutant and neuraminidase N294S mutant infected in MDCK cells assessed as inhibition of viral , EC50 = 1.341 μM. | 20350949 | ||
| MDCK | Antiviral assay | Inhibition of viral replication of influenza A virus (A/Hong Kong/213/03(H5N1)) and influenza A virus (A/Ann Arbor/6/60(H2N2)) hybrid virus in MDCK cells by neutral red uptake assay, EC50 = 2.6 μM. | 17194832 | ||
| MDCK | Antiviral assay | Inhibition of influenza A virus (A/duck/Minnesota/1525/1981 (H5N1)) replication in MDCK cells by virus yield reduction assay, EC90 = 2.6 μM. | 17194832 | ||
| MDCK | Antiviral assay | Antiviral activity against oseltamivir-susceptible zanamivir-, adamantane-resistant Influenza A virus (A/Luhansk/18/2008(H1N1)) harboring neuraminidase H274Y mutant and M2 G34E mutant infected in MDCK cells assessed as inhibition of viral replication afte, EC50 = 2.93 μM. | 20350949 | ||
| MDCK | Antiviral assay | Antiviral activity against adamantane-susceptible zanamivir-, oseltamivir-resistant Influenza A virus (A/duck/Vietnam/NCVD94/2007 clade 2.3.4 (H5N1)) harboring neuraminidase I117V mutant infected in MDCK cells assessed as inhibition of viral replication a, EC50 = 3.38 μM. | 20350949 | ||
| MDCK | Antiviral assay | Inhibition of viral replication of influenza A virus (A/Vietnam/1203/2004 (H5N1)) and influenza A virus (A/Ann Arbor/6/60(H2N2)) hybrid virus in MDCK cells by virus yield reduction assay, EC90 = 3.8 μM. | 17194832 | ||
| MDCK | Antiviral assay | Antiviral activity against oseltamivir-susceptible zanamivir-, adamantane-resistant Influenza A virus (A/Texas/12/2007 (clone)(H3N2)) harboring neuraminidase E119I mutant and harboring M2 S31N mutant infected in MDCK cells assessed as inhibition of viral , EC50 = 3.95 μM. | 20350949 | ||
| MDCK | Antiviral assay | Antiviral activity against oseltamivir-susceptible zanamivir-, adamantane-resistant Influenza A virus (A/Vietnam/HN30408/2005 H274Y clade 1 (H5N1)) harboring M2 L26I, S31N mutant and neuraminidase H274Y mutant infected in MDCK cells assessed as inhibition, EC50 = 4.14 μM. | 20350949 | ||
| MDCK | Antiviral assay | Inhibition of influenza A virus (A/duck/Minnesota/1525/1981 (H5N1)) replication in MDCK cells by neutral red uptake assay, EC50 = 4.5 μM. | 17194832 | ||
| MDCK | Antiviral assay | Antiviral activity against oseltamivir-susceptible zanamivir-, adamantane-resistant Influenza A virus (A/Texas/12/2007 (clone)(H3N2)) harboring neuraminidase E119V mutant and harboring M2 S31N mutant infected in MDCK cells assessed as inhibition of viral , EC50 = 5.22 μM. | 20350949 | ||
| MDCK | Antiviral assay | Antiviral activity against oseltamivir-susceptible zanamivir-, adamantane-resistant Influenza A virus (A/pdm/Washington/29/2009 (H1N1)) harboring M2 V28I, S31N mutant and neuraminidase H274Y mutant infected in MDCK cells assessed as inhibition of viral re, EC50 = 6.62 μM. | 20350949 | ||
| MDCK | Antiviral assay | Inhibition of Influenza A virus (A/gull/Pennsylvania/4175/83 (H5N1)) replication in MDCK cells by virus yield reduction assay, EC90 = 7.7 μM. | 17194832 | ||
| MDCK | Antiviral assay | Inhibition of Influenza A virus (A/gull/Pennsylvania/4175/83 (H5N1)) replication in MDCK cells by neutral red uptake assay, EC50 = 11.5 μM. | 17194832 | ||
| MDCK | Antiviral assay | Inhibition of viral replication of influenza A virus (A/Vietnam/1203/2004 (H5N1)) and influenza A virus (A/Ann Arbor/6/60(H2N2)) hybrid virus in MDCK cells by neutral red uptake assay, EC50 = 12.1 μM. | 17194832 | ||
| Vero-A | Antiviral assay | Antiviral activity against Chikungunya virus venturini isolate (Italy 2008) infected in African green monkey Vero-A cells assessed as inhibition of viral-induced cytopathic effect measured on day 7 post infection by MTS/PMS assay, EC50 = 16 μM. | 28689975 | ||
| MDCK | Antiviral assay | Antiviral activity against oseltamivir-susceptible zanamivir-, adamantane-resistant Influenza A virus (A/pdm/Illinois/10/2009(H1N1)) harboring M2 V28I, S31N mutant and neuraminidase H274Y mutant infected in MDCK cells assessed as inhibition of viral repli, EC50 = 22.48 μM. | 20350949 | ||
| Vero-A | Antiviral assay | Antiviral activity against Chikungunya virus 899 infected in African green monkey Vero-A cells assessed as inhibition of viral-induced cytopathic effect measured on day 7 post infection by MTS/PMS assay, EC50 = 25 μM. | 28689975 | ||
| Vero-A | Antiviral assay | Antiviral activity against Chikungunya virus LR2006-OPY1 infected in African green monkey Vero-A cells assessed as inhibition of viral-induced cytopathic effect measured on day 7 post infection by MTS/PMS assay, EC50 = 25 μM. | 28689975 | ||
| MDCK | Antiviral assay | Antiviral activity against 0.001 MOI adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza A virus (A/pdm/Mexico/4604/2009(H1N1)) harboring M2 V28I, S31N mutant infected in MDCK cells assessed as determination of viral titer in cell culture at, NULL = NULL μM. | 20350949 | ||
| MDCK | Antiviral assay | Antiviral activity against 0.001 MOI adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza A virus (A/pdm/California/04/2009(H1N1)) harboring M2 V28I, S31N mutant infected in MDCK cells assessed as determination of viral titer in cell culture , NULL = NULL μM. | 20350949 | ||
| 点击查看更多细胞系数据 | |||||
生物活性
| 产品描述 | Favipiravir (T-705)是一种有效的选择性RNA-dependent RNA polymerase抑制剂，用于治疗流感病毒感染。 | |
|---|---|---|
| 靶点 |
|
| 体外研究(In Vitro) | ||||
| 体外研究活性 | Favipiravir表现出抗流感病毒活性，对甲型流感病毒，乙型流感病毒和丙型流感病毒的IC50 范围分别为0.013-0.48 μg/ml，0.039-0.089 μg/ml，和0.030-0.057 μg/ml。在哺乳动物细胞系 (MDCK细胞，Vero细胞，HEL细胞，A549细胞，HeLa细胞，和HEp-2 细胞) 中，高达1,000 μg/ml 浓度的Favipiravir没有表现出毒性。[1]在接种季节性甲型流感(H1N1)病毒的MDCK细胞中，Favipiravir诱导致死性突变发生。[2] | |||
|---|---|---|---|---|
| 细胞实验 | 细胞系 | MDCK细胞，Vero细胞，HEL细胞，A549细胞，HeLa细胞，和 HEp-2 细胞 | ||
| 浓度 | 1000 μg/mL | |||
| 孵育时间 | 3天 | |||
| 方法 | T-705的毒性通过XTT试验评估。在MDCK细胞，Vero细胞，HEL 细胞，A549细胞，HeLa 细胞，和HEp-2细胞中，XTT通过酶转化为含水的甲臜。化合物用测试培养基(包含10% FCS的EMEM)在96孔板中(2 × 103细胞/100 μL)稀释为适当的浓度(体积，100 μl)。测试板在37°C，100% 湿度和5% CO2中培育3天。3天后，加入50 μl XTT试剂(在包含5 mM吩嗪硫酸甲酯的无FCS的EMEM中浓度为1 mg/ml)，反应产物使用酶标仪测量450 nm下的吸光度测定。细胞毒性表示为50% 细胞抑制浓度(CC50)。 | |||
| 实验图片 | 检测方法 | 检测指标 | 实验图片 | PMID |
| Growth inhibition assay | Survival Cell viability |
|
26711718 | |
| IHC | H&E Staining NiV nucleoprotein LASV antigen H&E stain |
|
29765101 | |
| Immunofluorescence | rNiV-Gluc |
|
29765101 | |
| 体内研究(In Vivo) | ||
| 体内研究活性 | 在流感病毒感染的小鼠中，Favipiravir (200 mg/kg/day, p.o.)保护小鼠不被流感病毒感染而死亡。[1]在人工感染Ebola病毒的小鼠中，Favipiravir有效阻断病毒产生，在治疗起始2天和6天后分别达到95%和99.6%的抗病毒效果。[3] | |
|---|---|---|
| 动物实验 | Animal Models | 感染流感病毒 A/PR/8/34的小鼠 |
| Dosages | 200 mg/kg/day | |
| Administration | p.o. | |
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT06024421 | Not yet recruiting | Infectious Disease|Pharmacology |
Institut National de la Santé Et de la Recherche Médicale France|FUJIFILM Toyama Chemical Co. Ltd. |
November 2023 | Phase 1 |
| NCT05940545 | Recruiting | CCHF |
Liverpool School of Tropical Medicine |
July 12 2023 | Phase 1|Phase 2 |
| NCT04907682 | Completed | Lassa Fever |
Bernhard Nocht Institute for Tropical Medicine|University of Hamburg-Eppendorf|Alliance for International Medical Action|Institut National de la Santé Et de la Recherche Médicale France|University of Bordeaux|Federal Medical Centre Owo|Irrua Specialist Teaching Hospital |
July 30 2021 | Phase 2 |
化学信息&溶解度
| 分子量 | 157.1 | 分子式 | C5H4FN3O2 |
| CAS号 | 259793-96-9 | SDF | Download Favipiravir (T-705) SDF |
| Smiles | C1=C(N=C(C(=O)N1)C(=O)N)F | ||
| 储存条件(自收到货起) | |||
|
体外溶解度 |
DMSO : 31 mg/mL ( (197.32 mM)； DMSO吸湿会降低化合物溶解度，请使用新开封DMSO) Water : 2 mg/mL Ethanol : 2 mg/mL |
摩尔浓度计算器 |
|
体内溶解度 现配现用，请按从左到右的顺序依次添加，澄清后再加入下一溶剂 |
动物体内配方计算器 | ||||
实验计算
动物体内配方计算器（澄清溶液）
第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）
mg/kg
g
μL
只
第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系Selleck为您提供正确的澄清溶液配方）
% DMSO
%
% Tween 80
% ddH2O
%DMSO
%
计算结果：
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于μL DMSO溶液（母液浓度mg/mL，注：如该浓度超过该批次药物DMSO溶解度，请先联系Selleck）；
体内配方配制方法：取μL DMSO母液，加入μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入μL ddH2O，混匀澄清。
体内配方配制方法：取μL DMSO母液，加入μL Corn oil，混匀澄清。
注意：1. 首先保证母液是澄清的；
2.一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
技术支持
在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。
如果有其他问题，请给我们留言。
* 必填项
Tags: buy Favipiravir (T-705) | Favipiravir (T-705) supplier | purchase Favipiravir (T-705) | Favipiravir (T-705) cost | Favipiravir (T-705) manufacturer | order Favipiravir (T-705) | Favipiravir (T-705) distributor
